HOME >> MEDICINE >> NEWS
New data supports CellCept's position as a world leader in solid organ transplantation

m creatinine levels were observed over two years, reinforcing CellCept's nephroprotective profile.

Grostzner J, Kaczmarek I, Mueller M, et al. Calcineurin-inhibitor-free immunosuppression with mycophenolate mofetil and sirolimus after cardiac transplantation is safe and improves renal function significantly: 1 year follow-up. Abstract 449, ATC 2004.
In this study of 30 heart transplant patients data showed that conversion from a CNI-based immunosuppressant regimen to CellCept and sirolimus in patients with chronic kidney failure is safe, preserves graft function and improves kidney function. This may help avoid CNI-related nephrotoxicity, a common problem after heart transplantation, which can lead to increased morbidity and impairment of patients' quality of life.

in adult kidney transplant patients
Abramowicz D, Gafner N, Wijngaard P. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomised study. Abstract 1527, ATC 2004.
In a study of 151 stable renal transplant patients, where CNI was withdrawn from a CellCept-based immunosuppressant regimen, there was no impact on five-year graft and patient survival. Beneficial effects were observed in kidney function, as well as lipid profile, blood pressure and malignancy rate. These data show that CellCept is safe to use long term as part of a low-toxicity immunosuppressant regimen and allows CNI-sparing, thus avoiding associated kidney toxicity, high cholesterol and high blood pressure, which can lead to impaired graft function.

Kessler M, Frimat L, Charpentier B, et al. Renal function evaluation after half dose reduction of Neoral in combination with CellCept in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF REFERENCE study: a randomised, open, multicentre, prospective, controlled study. Abstract 462, ATC 20
'"/>

Contact: Cendrine Banerjee-Quetel
cendrine.banerjee-quetel@ketchum.com
44-207-611-3656
Ketchum
19-May-2004


Page: 1 2 3 4 5

Related medicine news :

1. Emergency department study supports giving dehydrated children fluids by mouth
2. Review supports link between HRT and stroke
3. Chamomile tea: New evidence supports health benefits
4. Social supports lessen effects of maltreatment on children vulnerable to depression
5. Study supports the use of mechanical assistance
6. Study supports aggressive treatment of heart patients with cholesterol-lowering medication
7. NCI grant supports Jefferson trial to study test for colorectal cancer recurrence
8. Study supports new theory for nicotines protective effect against neurodegenerative disorders
9. New study supports use of PET scans in early diagnosis of Alzheimers disease
10. Contraception study supports convenience, simplicity
11. International grant supports study related to preventing organ rejection

Post Your Comments:
(Date:10/30/2014)... Amy Norton HealthDay Reporter ... common plastics, chemical during pregnancy may have effects on genital ... found that baby boys born to moms with greater exposure ... anogenital distance -- the space between the genitals and anus. ... a marker of exposure to androgens ("male" hormones) during pregnancy. ...
(Date:10/30/2014)... (HealthDay News) -- Eating a low-carb, high-fat diet could ... to new research. A review of five ... that focuses on foods like bacon, eggs, heavy cream, ... in adults whose condition doesn,t improve with medication. ... people with epilepsy whose seizures are not stopped by ...
(Date:10/30/2014)... care respects the fact that a patient,s body ... treatment. Over a third of cancer patients experience ... their conditions. And, increasingly, care providers are exploring ... navigate mental health challenges. A University of Colorado ... Psycho-Oncology asks an important question: after ...
(Date:10/29/2014)... – Many of the women at first acted surprised. Some ... researchers why they had not used the study products assigned ... trial that, as a likely consequence, did not find any ... , The women were among 127 former VOICE participants ... agreed to take part in in-depth interviews and/or focus group ...
(Date:10/28/2014)... the inner and outer body and organ surfaces in ... pancreas and in the inner ear," said Moritz Gegg. ... BBs and are precisely positioned on many of these ... movements be coordinated so precisely that for example mucus ... be perceived from sensory inner ear hair cells," added ...
Breaking Medicine News(10 mins):Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3Health News:Decades of research: Effectiveness of phone counseling for cancer patients still unknown 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 3Health News:New insights into the development of ciliopathies 2
(Date:10/30/2014)... 2014 Boston Scientific Corporation (NYSE: ... Credit Suisse Annual Healthcare Conference on Tuesday, November 11, ... Dan Brennan , executive vice president and chief financial ... at approximately 8:00 a.m. PT followed by a question ... the presentation and question and answer session will be ...
(Date:10/30/2014)... ANGELES , Oct. 30, 2014   ... company devoted to bringing new products to market, ... drug called TetraStem. TetraStem is a topical liquid ... delivery system that can convert oral medication active ... registered as a first aid antibiotic to help ...
(Date:10/30/2014)... CVS Health (NYSE: CVS ) announced ... leading regional health systems to enhance access to high-quality, affordable ... Baptist Health System in Alabama ; Community ... Pennsylvania , Northwest Medical Center, including Oro ... Healthcare in Tennessee ; and Premier Health ...
Breaking Medicine Technology:Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4
Cached News: